[6-fluoro-4-(1-isobutyrylpiperidin-4-yloxy)naphthalen-2-yl]acetic acid | 1227257-78-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: [6-fluoro-4-(1-isobutyrylpiperidin-4-yloxy)naphthalen-2-yl]acetic acid
• 英文别名: 2-[6-Fluoro-4-[1-(2-methylpropanoyl)piperidin-4-yl]oxynaphthalen-2-yl]acetic acid
• CAS: 1227257-78-4
• 化学式: C₂₁H₂₄FNO₄
• 分子量: 373.424
• InChiKey: WNOJTCMXBYHPPS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• NAPHTHYLACETIC ACIDS
  申请人：Firooznia Fariborz

  公开号：US20100125061A1

  公开（公告）日：2010-05-20

  The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein X, Q and R 1 -R 3 are defined in the detailed description and claims. The invention is also concerned with the compounds of formula Z: and pharmaceutically acceptable salts and esters thereof, wherein R 1 -R 3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I and Z as well as pharmaceutical compositions containing such compounds. The compounds of formula I and Z are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

  这项发明涉及公式I的化合物： 以及其药学上可接受的盐和酯，其中X、Q和R1-R3在详细说明和索赔中有定义。该发明还涉及公式Z的化合物： 以及其药学上可接受的盐和酯，其中R1-R3在详细说明和索赔中有定义。此外，本发明涉及制造和使用公式I和Z的化合物的方法，以及含有这些化合物的药物组合物。公式I和Z的化合物是CRTH2受体的拮抗剂或部分激动剂，可能在治疗与该受体相关的疾病和紊乱方面有用，如哮喘。
• NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2358677A1

  公开（公告）日：2011-08-24
• US8188090B2
  申请人：——

  公开号：US8188090B2

  公开（公告）日：2012-05-29
• [EN] NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS<br/>[FR] ACIDES NAPHTYLACÉTIQUES EMPLOYÉS EN TANT QU'ANTAGONISTES OU AGONISTES PARTIELS DE CRTH2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010055006A1

  公开（公告）日：2010-05-20

  The invention is concerned with the compounds of formula I and pharmaceutically acceptable salts and esters thereof, wherein X, Q and R1 -R3 are defined in the detailed description and claims. The invention is also concerned with the compounds of formula Z and pharmaceutically acceptable salts and esters thereof, wherein R1-R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I and Z as well as pharmaceutical compositions containing such compounds. The compounds of formula I and Z are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.